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Impaired Cognitive Functioning in Patients with Tyrosinemia Type I
Receiving Nitisinone
Fatiha Bendadi1, Tom J. de Koning1, Gepke Visser1, Hubertus C. M. T. Prinsen2, Monique G. M. de Sain2, Nanda Verhoeven-
Duif2, Gerben Sinnema3, Francjan J. van Spronsen4, and Peter M. van Hasselt1
Objective To examine cognitive functioning in patients with tyrosinemia type I treated with nitisinone and a
protein-restricted diet.
Study design We performed a cross-sectional study to establish cognitive functioning in children with tyrosine-
mia type I compared with their unaffected siblings. Intelligence was measured using age-appropriate Wechsler
Scales. To assess cognitive development over time, we retrieved sequential IQ scores in a single-center subset
of patients. We also evaluated whether plasma phenylalanine and tyrosine levels during treatment was correlated
with cognitive development.
Results Average total IQ score in 10 patients with tyrosinemia type I receiving nitisinone was significantly lower
compared with their unaffected siblings (71  13 vs 91  13; P = .008). Both verbal and performance IQ subscores
differed (77 14 vs 95 11; P < .05 and 70 11 vs 87 15; P < .05, respectively). Repeated IQmeasurements in a
single-center subset of 5 patients revealed a decline in average IQ score over time, from 96  15 to 69  11 (P <
.001). No significant association was found between IQ score and either plasma tyrosine or phenylalanine concen-
tration.
Conclusion Patients with tyrosinemia type I treated with nitisinone are at risk for impaired cognitive function
despite a protein-restricted diet. (J Pediatr 2014;164:398-401).
H
ereditary tyrosinemia type I (OMIM 276700) is the most frequent inborn error of tyrosine degradation and results from
a defect in fumarylacetoacetate hydrolase (EC 3.7.1.2). Without treatment, the accumulation of toxic metabolites,
particularly maleylacetoacetate and fumarylacetoacetate, induces organ dysfunction and carcinogenesis. Patients
may present within weeks of birth with gastrointestinal bleeding and liver failure, or later in childhood with failure to thrive,
peripheral neuropathy, hepatic cirrhosis, and renal Fanconi syndrome.1 Hepatocellular carcinoma is a frequent cause of death
in early childhood.
Introduction of the drug 2-[2-nitro-4-trifluoromethylbenzoyl]-1, 3-cyclohexanedione (NTBC) in 1992 has dramatically
improved the survival of patients with tyrosinemia type I.2,3 NTBC, now marketed as nitisinone, prevents the accumulation
of toxic metabolites by blocking an upstream enzyme, 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), in the tyrosine
degradation pathway.3 Before the introduction of NTBC, the mortality rate in children diagnosed early (age <2 months) was
75% at age 2 years and >90% by age 12 years.4,5 Long-term survival was attained only in those who underwent successful or-
thoptic liver transplantation after the discovery of hepatocellular carcinoma.6 With the advent of NTBC, liver dysfunction is
now controlled in >90% of patients, and extrahepatic manifestations have been abolished.7 The risk of liver cancer has been
reduced as well.8-10 As a consequence, death in childhood has become a rare event.11 Concerns whether increased survival is
attained at the expense of reduced cognitive functioning remain, however.
Nitisinone biochemically switches the enzymatic defect from tyrosinemia type I to tyrosinemia type III, inducing elevated
tyrosine concentrations up to 1500 mmol/L (normal, 40-90 mmol/L) when dietary treatment is not provided.7 Increased tyro-
sine levels are considered responsible for the impaired cognitive function in patients with tyrosinemia type II and III.1 Whether
a phenylalanine- and tyrosine-restricted diet aimed at reducing plasma tyrosine concentrations to <500 mmol/L is sufficient to
prevent cognitive damage is unknown.
The aim of the present study was to evaluate cognitive functioning in patients with tyrosinemia type I during nitisinone treat-
ment on a protein-restricted diet by comparing their IQ scores with those of their healthy siblings.From the 1Department of Metabolic Diseases,
NTBC
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2Department of Medical Genetics, Section Metabolic
Diagnostics, and 3Department of Pediatric Psychology,
University Medical Center Utrecht, Utrecht, The
Netherlands and 4Division of Metabolic Diseases, Beatrix
Children’s Hospital, University Medical Center ofPatients with tyrosinemia type I were retrieved from 2 Dutch centers, University
Medical Center Utrecht and University Medical Center Groningen. Patients agedGroningen, University of Groningen, Groningen, The
Netherlands
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2-[2-nitro-4-trifluoromethylbenzoyl]-1, 3-cyclohexanedione
Vol. 164, No. 2  February 2014>3 yearswho had ever been treatedwith nitisinone (at a dose of
0.8-2 mg/kg) and a protein-restricted diet were included.
Exclusion criteria were lack of parental consent and failure to
performreliable IQ testing.Unaffected siblings,when available,
served as controls. In the event that more siblings were eligible
within the same family, the sibling in the same age category as
the patient was asked toparticipate, to allow the use of the same
IQ test and to optimize the comparison of the patient and
control. A waiver of requirement for informed consent was
granted by the Institutional Review Board of the University
Medical Center Utrecht, which reviewed the study.
Cognitive functioning was assessed using age-appropriate
Wechsler Scale IQ tests (Wechsler Preschool and Primary
Scale of Intelligence-Revised for age 3-7 years, Wechsler In-
telligence Scale for Children-Third Edition for age 7-17 years,
and Wechsler Adult Intelligence Scale-Third Edition for age
18 years and older). These Wechsler tests provide 3 scores:
a verbal IQ score, a performance IQ score, and a composite
single total IQ score. The mean  SD score of these tests is
100  15. Assessments took place at the participant’s
home, in a quiet room, during the daytime by a single inves-
tigator. The test results for the patients were compared with
the results for the controls as well as with scores of IQ tests
performed previously, when available.
Earlier studies have suggested that both tyrosine levels and
phenylalanine levels may play a role in cognitive develop-
ment.6,9 To monitor the effect of dietary restriction, plasma
amino acid concentrations, including phenylalanine and tyro-
sine, were determined at 3-month intervals during follow-up.
These datawere retrieved frompatient records.Data on clinical
manifestations during follow-up, particularly those suggestive
of high levels of plasma tyrosine (particularly keratitis), were
also collected from hospital records. Parental education, pro-
fession, and socioeconomic status were assessed using a ques-
tionnaire. The questionnaire also addressed siblings’ school
performance and health, including the use of medication.
Statistical analyses were performed using SPSS version
14.0 (SPSS, Chicago, Illinois). By defining the skewness
(0.04  0.524), we found a normal distribution of the IQ
scores and used the parametric Student t test to test for
within-group IQ differences between patients and controls.Table. Baseline characteristics of patients with tyrosinemia ty
Patient
Age at time
of study, y Sex
Age at
diagnosis, mo




1* 20 Male 3 78 Yes
2 20 Female 9 72 No†
3 16 Male 6 6 Yes
4 14 Male 8 8 Yes
5 13 Male 3 3 Yes
6 13 Male 24 24 Noz
7* 11 Male 0 0 Yes
8 10 Male 6 6 Yes
9 9 Male 4 4 Yes
10 5 Female 3 3 Yes
SES, socioeconomic status.
*Patients 1 and 7 are siblings.
†At age 18 y.
zAt age 8 y.We used the paired Student t test to investigate the difference
between paired patients and their unaffected siblings. We
used Pearson correlation to examine relationships between
performance on the IQ test and metabolic parameters in
the patients with tyrosinemia type I. A significance level of
P < .05 was used for all tests.
Results
Sixteen eligible patients with tyrosinemia type I were
retrieved. Six patients were excluded, 4 patients because of
lack of parental consent and 2 (3 years old) patients because
reliable IQ testing could not be accomplished owing to signif-
icant developmental delay. Eight of the remaining 10 patients
were treated with nitisinone and a protein-restricted diet at
the time of testing, whereas 2 had received nitisinone for
more than 10 years before undergoing liver transplantation
(Table). In 7 families, an unaffected sibling served as a control.
Cognitive Measures
The mean total IQ was 71 (range, 58-84) in patients with ty-
rosinemia type I and 91 (range, 78-104) in their healthy sib-
lings. In patients with tyrosinemia, mean performance IQ
was 70 (range, 59-81) and mean verbal IQ was 77 (range,
63-91) compared with 87 (range, 72-102) and 95 (range,
84-106) in their healthy siblings. The IQ difference was
seen on both subscales and remained significant when only
patients with an available sibling were analyzed (71 vs 91; P
= .006). The 2 patients who were no longer treated with niti-
sinone and a protein-restricted diet after undergoing liver
transplantation had similarly low IQ levels. Low IQ scores
were associated with special education attendance (r =
0.0677; P = .036).
In search of an explanation for these findings, we next
focused on a subset of 5 patients from a single center. In
this center, IQ tests were repeated at 2- to 3-year intervals
as a regular part of follow-up. We reasoned that a stable IQ
over time would point toward preexisting factors, whereas
a decline in IQ would suggest ongoing damage during—
and perhaps due to—treatment. As depicted in Figure 1,








sibling included Education SES
No Yes Yes Regular Low
Yes No Yes Regular Low
No Yes Yes Regular Middle
No Yes Yes Regular Middle
No Yes Yes Special Low
Yes No No Special Middle
No Yes Yes Regular Low
No Yes Yes Special Low
No No Yes Regular High
No No No Regular Middle
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Figure 1. Longitudinal IQ levels in patients with tyrosinemia
type I receiving nitisinone. A significant drop of total IQ (an
average of 27 IQ points; P < .001) can be seen.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 164, No. 2patients, but a significant decline in their total IQ scores was
observed during follow-up. The average total IQ dropped
from 96  15 to 69  11 between each patient’s first and
last measurement, a decline of 27 IQ points (P < .001).
IQ and Metabolic Control
To investigate the relationship between IQ and the degree of
metabolic control, we analyzed plasma tyrosine and phenylal-
anine levels in the 8 patients treated with nitisinone and a
protein-restricted diet (Figure 2). Plasma tyrosine was
elevated in all patients (mean, 511  168 mmol/L). Although
the mean plasma phenylalanine level was within the normalFigure 2. Tyrosine and phenylalanine plasma concentrations in p
indicate reference values. The dashed line indicates the therapeu
alanine levels by age. C, Correlation between plasma tyrosine an
400range (mean, 37  14 mmol/L), a substantial proportion
(24%) of measured values were below the lower limit of the
normal range (25 mmol/L). A significant correlation was
found between tyrosine levels and phenylalanine levels (r =
0.411; P = .001) (Figure 2, A). Both tyrosine and
phenylalanine levels increased with age (r = 0.087; P < .001
and r = 0.144; P < .001, respectively). Neither plasma
tyrosine nor phenylalanine level was correlatedwith IQ indices.Discussion
Our findings show that patients with tyrosinemia type I
treated with nitisinone are at risk for developing impaired
cognitive function despite a protein-restricted diet. Treating
patients with tyrosinemia type I with a combination of niti-
sinone and a protein-restricted diet has brought about im-
provements in both life expectancy and disease-related
morbidity. Consequently, patients with tyrosinemia type I
are now likely to reach adulthood. This makes the major
finding reported here—an average IQ of 71, 20 IQ points
lower than their unaffected siblings—of both clinical and so-
cial relevance.
To control for genetic and/or environmental background,
we compared IQ scores in our patients and their siblings. The
somewhat lower average IQ in healthy siblings compared
with the general population supports the usefulness of this
approach. Notwithstanding, the IQ of the patients was sub-
stantially lower than that of their siblings. These patients’
poor school performance corroborates a previous finding re-
ported by Masurel-Paulet et al13 and underscores that theatients with tyrosinemia type I receiving nitisinone. Gray areas
tic target. A, Plasma tyrosine level by age. B, Plasma phenyl-
d phenylalanine levels.
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February 2014 ORIGINAL ARTICLESsignificantly lower IQ is of clinical relevance. One of the main
strengths of the present study is the actual availability of IQ
levels, including those over time. IQ testing in this center
was not performed on a “clinical suspicion” basis, which
obviously would have represented a selection bias, but rather
was performed routinely in all patients based on initial con-
cerns regarding the long-term cognitive effects of nitisinone.
The nature of the observed cognitive impairment remains
enigmatic. Mild impaired cognitive functionmay have been a
“missed” feature of tyrosinemia type I, a symptom that we
failed to recognize before the use of nitisinone because of
the short life span of untreated patients with tyrosinemia
type I. Unfortunately, there are no animal data known to
us to either support or refute this hypothesis. Nonetheless,
we are aware of adults with tyrosinemia and normal cognitive
function.14 The lower IQ may be an unwanted side effect of
treatment. In support, a significant decrease in IQ was noted
in a subset of patients in whom IQ was regularly tested. The
finding of similarly low IQs in patients who had stopped tak-
ing nitisinone after undergoing liver transplantation argues
against the acute toxicity of nitisinone itself. Most likely, ni-
tisinone affects cognitive function indirectly, by inducing
profoundly elevated plasma tyrosine levels. The lack of corre-
lation between IQ and tyrosine levels in our population may
be related to the limited sample size or other issues with re-
gard to tyrosine measurement.
Tyrosine levels can be reduced through a more restricted
protein intake; however, this measure may be detrimental if
it induces lower phenylalanine levels. Because phenylalanine
and tyrosine compete for transport to the brain, the combi-
nation of high tyrosine and low phenylalanine may lead to
insufficient phenylalanine transport to the brain, decreasing
the amount of phenylalanine available for protein and neuro-
transmitter synthesis. According to some authors, this
shortage may cause a deviant cognitive development that
can be expressed later in life with mildly impaired cognitive
function.12,13,15 Hopefully, data on the effects of a more
restrictive diet will become available. Based on our data, we
recommend that the follow-up of patients with tyrosinemia
type I include routine cognitive assessment. n
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